COMPANY PROFILE

Tr1x

Explore full profile

Providing subscribers with access to exclusive content

San Diego, United StatesFounded 2018Biotech & Life Sciences

Valuation $250–500M Last recorded · 2025

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Tr1x

Tr1X Inc. is a biotechnology company focused on creating novel cellular immunotherapies for patients suffering from autoimmune and inflammatory diseases. Utilizing a proprietary platform, Tr1X generates first-in-class cell therapy products designed to rebalance the immune system and restore homeostasis, ultimately leading to long-term tolerance. Headquartered in La Jolla, CA, the company operates within the biopharmaceutical market, targeting healthcare providers and patients in need of advanced therapeutic solutions. Tr1X's business model revolves around the development and commercialization of its unique cell therapy products, generating revenue through partnerships, licensing agreements, and direct sales.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2018
Headquarters: San Diego, United States
Employees: 46
Open positions: 1
Dealroom signal: 83.4/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2c
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VCOther financing	Oct 2025	$50M	$375M	Undisclosed	↗
SERIES AOther financing	Jan 2024	$75M	$300M	Alexandria Venture Investments · NEVA SGR · The Column Group	↗

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Tr1x website traffic

Latest recorded traffic for Tr1x is 3.1K monthly website visits, up 47.6% over the last three months. Tr1x's team grew 12.2% over the past year.

Latest monthly visits3.1K 3-month web change+47.6% 1-year team growth+12.2%

Monthly website visitsDec 2023–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Senior Manager, Lab Operations New San Diego, CASan Diego, California, United States, Northern America, Americas · Other · Sep 2, 2026 Principal Scientist, LNP Platform & Process Development New San Diego, CASan Diego, California, United States, Northern America, Americas · Other · Sep 2, 2026 Senior Director, QualitySan Diego, California, United States, Northern America, Americas · Human Resources · Jul 28, 2026

3 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
DIDIADEMImproves clinicians/patient understanding about risk of Dementia/Alzheimer’s to enable earlier decisions and outcome	London, United Kingdom	Operational	10	$14M	$44M
BBBrixton BiosciencesBrixton Biosciences develops innovative therapies for chronic pain	Cambridge, United States	Operational
EBEnable BiosciencesUltrasensitive antibody detection platform for the early diagnosis of diseases, including Type 1 Diabetes and HIV	South San Francisco, United States	Operational
IKIkarovecBi-functional gene therapies for chronic eye diseases	Norwich, United Kingdom	Operational
RBRevolo BiotherapeuticsDeveloping revolutionary therapies powered to reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases	Gaithersburg, United States	Operational
NTNightStar TherapeuticsAAV gene therapies for inherited retinal diseases	London, United Kingdom	Acquired
IPIntract PharmaOral delivery technologies for biologic and antibody drugs	London, United Kingdom	Operational
GTGyroscope TherapeuticsDeveloping one-time gene therapies for retinal diseases	London, United Kingdom	Acquired